AFFY  Affymax Inc.

Exchange

NASDAQ

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

2.89M

Current Price

$0.08
+0.003 (+3.704%)

Book Price

$-0.20
Overvalued by 354.66%
Financial Institution

Company Metrics

  • P/E 0.939
  • P/S 66.279
  • P/B 0.538
  • EPS 0.082
  • Dividend 0 / 0%
  • Avg. Vol. 25,998.00
  • Shares 37.53M
  • Market Cap. 2.89M

Company Description

Affymax, Inc., a biopharmaceutical company, engages in the development of drugs for the treatment of serious and life-threatening conditions. The company is developing Hematide, which is in Phase III clinical trials for the treatment of anemia associated with chronic renal failure. Hematide is a synthetic peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood ... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Affymax, Inc. Announces a Special Cash Distribution and the Appointment of a ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) today announced that its Board of Directors has declared a special cash distribution to shareholders in the amount of $0.05 per share.
Affymax Likely Worthless: Omontys Kills At Least 9x More People Than Epogen
Seeking Alpha - Aug 28, 2013
Affymax, Inc. (OTCPK:AFFY) is a shell company that owns potential future royalty and milestone payments associated with the recently recalled drug Omontys (peginesatide).
Affymax: Emerging Data Supports Conclusion Omontys Likely Dead
Seeking Alpha - Nov 12, 2013
After reviewing the summary adverse event report data highlighting a shocking number of deaths associated with Omontys, (discussed here), we followed-up with the FDA to request more information.
Affymax, Inc. (OTCMKTS:AFFY) Crashes After Losing Partner
HotStocked - Jun 17, 2014
Yesterday's market session was a real disaster for Affymax, Inc. (OTCMKTS:AFFY, AFFY message board). Once the 8-K announcing that the partnership AFFY had with Takeda has been terminated affected the market, the company lost 54.55% of its share ...
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide ...
GlobeNewswire (press release) - Jul 18, 2013
Delisting of Securities of Telestone Technologies Corp, Affymax, Inc., Exide Technologies, Orchard Supply Hardware Stores Corporation, Spire Corporation and Shengkai Innovations, Inc. From The NASDAQ Stock Market ...
Affymax: Putting The Pieces Together
Seeking Alpha - Aug 24, 2013
Affymax's sole drug product is OMONTYS┬« (peginesatide) Injection ("OMONTYS"), which was approved by the FDA in 2012 and well received by the medical community as a treatment for anemia due to chronic kidney disease (CKD) in adult patients on ...
Affymax, Inc. (NASDAQ:AFFY) Stock Shoots Up
HotStocked - Aug 9, 2010
On Friday, one month after the last deep plunge of Affymax, Inc. (NASDAQ:AFFY, AFFY message board) stock, a completely different scenario proved investor willingness to support the shares' upward direction.
The end for Affymax
Seeking Alpha - Jun 24, 2014
With no hope for a return to the market for Omontys, Affymax's (AFFY) BOD approves the liquidation and dissolution of the company, subject to shareholder approval.
Affymax Board Announces Decision to Dissolve the Company - Business Wire (press release)
Affymax Board Approves Dissolving Troubled Company - Genetic Engineering News
Affymax stock plunges 85 percent on drug recall
Reuters - Feb 25, 2013
Shares of Affymax Inc AFFY.O fell 85 percent after it said serious adverse reactions, including death, were reported among some of those using its sole commercial product, anemia drug Omontys.
Affymax and Takeda Announce a Nationwide Voluntary Recall of All Lots of ... - Business Wire (press release)
Affymax Plunges After Recall of Omontys due to Reactions - Bloomberg
Affymax Adopts Tax Benefit Preservation Plan to Protect Net Operating Loss ...
Business Wire (press release) - Nov 26, 2014
CUPERTINO, Calif.--(BUSINESS WIRE)--Affymax, Inc. (OTCQB: AFFY) announced today that its Board of Directors has adopted a Tax Benefit Preservation Plan, or Rights Plan, in an effort to preserve the value of its significant net operating loss ...